

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJMN1626

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 MAY 01 New CAS web site launched
NEWS 3 MAY 08 CA/CAPplus Indian patent publication number format defined
NEWS 4 MAY 14 RDISCLOSURE on STN Easy enhanced with new search and display fields
NEWS 5 MAY 21 BIOSIS reloaded and enhanced with archival data
NEWS 6 MAY 21 TOXCENTER enhanced with BIOSIS reload
NEWS 7 MAY 21 CA/CAPplus enhanced with additional kind codes for German patents
NEWS 8 MAY 22 CA/CAPplus enhanced with IPC reclassification in Japanese patents
NEWS 9 JUN 27 CA/CAPplus enhanced with pre-1967 CAS Registry Numbers
NEWS 10 JUN 29 STN Viewer now available
NEWS 11 JUN 29 STN Express, Version 8.2, now available
NEWS 12 JUL 02 LEMBASE coverage updated
NEWS 13 JUL 02 LMEDLINE coverage updated
NEWS 14 JUL 02 SCISEARCH enhanced with complete author names
NEWS 15 JUL 02 CHEMCATS accession numbers revised
NEWS 16 JUL 02 CA/CAPplus enhanced with utility model patents from China
NEWS 17 JUL 16 CAPplus enhanced with French and German abstracts
NEWS 18 JUL 18 CA/CAPplus patent coverage enhanced
NEWS 19 JUL 26 USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS 20 JUL 30 USGENE now available on STN
NEWS 21 AUG 06 CAS REGISTRY enhanced with new experimental property tags
NEWS 22 AUG 06 BEILSTEIN updated with new compounds
NEWS 23 AUG 06 FSTA enhanced with new thesaurus edition
NEWS 24 AUG 13 CA/CAPplus enhanced with additional kind codes for granted patents
NEWS 25 AUG 20 CA/CAPplus enhanced with CAS indexing in pre-1907 records
NEWS 26 AUG 27 Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 27 AUG 27 USPATOLD now available on STN
NEWS 28 AUG 28 CAS REGISTRY enhanced with additional experimental spectral property data

NEWS 29 SEP 07 STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 30 SEP 13 FORIS renamed to SOFIS
NEWS 31 SEP 13 INPADOCDB: New SDI frequency MONTHLY available now

NEWS EXPRESS 05 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 05 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 12:08:15 ON 15 SEP 2007

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:08:24 ON 15 SEP 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 SEP 2007 HIGHEST RN 947298-73-9

DICTIONARY FILE UPDATES: 14 SEP 2007 HIGHEST RN 947298-73-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10510469\1.str



```

chain nodes :
1  2  3  4  5  6  7  8  9  13  14  17  18  19  20  23
chain bonds :
1-2  1-17  2-3  2-8  2-23  3-4  3-7  4-5  4-6  5-13  8-9  13-14  17-18  17-19
18-20
exact/norm bonds :
1-2  1-17  2-23  3-7  4-5  4-6  5-13  8-9  13-14  17-18  17-19  18-20
exact bonds :
2-3  2-8  3-4

```

G1:H,N

G2:O,S

G3:H,CH3

```

Match level :
1:CLASS  2:CLASS  3:CLASS  4:CLASS  5:CLASS  6:CLASS  7:CLASS  8:CLASS  9:CLASS
13:CLASS 14:Atom  17:CLASS 18:CLASS 19:CLASS 20:Atom  23:CLASS


```

L1 STRUCTURE UPLOADED

```

=> d
L1 HAS NO ANSWERS
L1 STR

```



G1 H,N

G2 O,S

G3 H,Me

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 12:08:42 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 185 TO ITERATE

100.0% PROCESSED 185 ITERATIONS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
 BATCH **COMPLETE**

PROJECTED ITERATIONS: 2884 TO 4516

PROJECTED ANSWERS: 4 TO 200


L2 4 SEA SSS SAM L1

=> d scan

4 ANSWERS

L2 4 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]-,
(3S)-4,4-dimethyl-1-[(3-phenoxyphenyl)acetyl]-3-pyrrolidinyl ester (9CI)
MF C36 H43 N3 O6

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l1 full

FULL SEARCH INITIATED 12:08:55 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 3613 TO ITERATE

100.0% PROCESSED 3613 ITERATIONS

86 ANSWERS

SEARCH TIME: 00.00.01

L3 86 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

172.10

172.31

FILE 'CAPLUS' ENTERED AT 12:09:02 ON 15 SEP 2007

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Sep 2007 VOL 147 ISS 13

FILE LAST UPDATED: 14 Sep 2007 (20070914/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3

L4

3 L3


=> d ibib abs hitstr 1-3

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN
 ACCESSION NUMBER: 2006:128532 CAPLUS
 DOCUMENT NUMBER: 144:304509
 TITLE: Novel, potent P2-P3 pyrrolidine derivatives of
 ketoamide-based cathepsin K inhibitors
 AUTHOR(S): Barrett, David G.; Catalano, John G.; Deaton, David
 N.; Hassell, Anne M.; Long, Stacey T.; Miller, Aaron
 B.; Miller, Larry R.; Ray, John A.; Samano, Vicente;
 Shewchuk, Lisa M.; Wells-Knecht, Kevin J.; Willard,
 Derril H.; Wright, Lois L.
 CORPORATE SOURCE: Department of Medicinal Chemistry, GlaxoSmithKline,
 Research Triangle Park, NC, 27709, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2006),
 16(6), 1735-1739
 CODEN: BMCLEB; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 144:304509

AB Starting from a potent pantolactone ketoamide cathepsin K inhibitor
 discovered from structural screening, conversion of the lactone scaffold
 to a pyrrolidine scaffold allowed exploration of the S3 subsite of
 cathepsin K. Manipulation of P3 and P1' groups afforded potent inhibitors
 with drug-like properties.


IT 615554-82-OP 615554-84-2P 615555-54-9P
 615555-56-1P 615555-57-2P 615555-61-8P
 615555-67-4P 615555-71-OP 615555-72-1P
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN
 (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); USES (Uses)
 (pyrrolidine derivs. of ketoamide-based cathepsin K inhibitors)
 RN 615554-82-0 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethylamino]acetyl]pentyl]-,
 (3S)-4,4-dimethyl-1-(phenylacetyl)-3-pyrrolidinyl ester (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.




RN 615554-84-2 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethylamino]acetyl]pentyl]-,
 (3S)-1-(5-isoxazolylcarbonyl)-4,4-dimethyl-3-pyrrolidinyl ester (9CI)
 (CA INDEX NAME)

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 Absolute stereochemistry.




RN 615555-61-8 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1H-pyrazol-3-ylamino)acetyl]pentyl]-,
 (3S)-4,4-dimethyl-1-[[4-(trifluoromethyl)phenyl]amino]carbonyl]-3-
 pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 615555-67-4 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethylamino]acetyl]pentyl]-,
 (3S)-4,4-dimethyl-1-(phenylsulfonyl)-3-pyrrolidinyl ester (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.




RN 615555-71-0 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1H-pyrazol-3-ylamino)acetyl]pentyl]-,

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 Absolute stereochemistry.




RN 615555-54-9 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethylamino]acetyl]pentyl]-,
 (3S)-4,4-dimethyl-1-[[4-(phenylmethyl)amino]carbonyl]-3-pyrrolidinyl ester
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 615555-56-1 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethylamino]acetyl]pentyl]-,
 (3S)-4,4-dimethyl-1-(3-pyridinylcarbonyl)-3-pyrrolidinyl ester (9CI) (CA
 INDEX NAME)


Absolute stereochemistry.



RN 615555-57-2 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethylamino]acetyl]pentyl]-,
 (3S)-1-[[4-(3,5-dimethyl-4-isoxazolyl)amino]carbonyl]-4,4-dimethyl-3-
 pyrrolidinyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 (3S)-1-(2-benzothiazolyl)-4,4-dimethyl-3-pyrrolidinyl ester (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.



RN 615555-72-1 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1H-pyrazol-3-ylamino)acetyl]pentyl]-,
 (3S)-4,4-dimethyl-1-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]-3-
 pyrrolidinyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 615554-78-4P 615554-94-4P 615554-96-6P
 615555-00-5P 615555-02-7P 615555-09-4P
 615555-30-1P 615555-34-5P 615555-35-6P
 615555-47-0P 615555-50-5P 615555-53-8P
 615555-55-0P 615555-60-7P 615555-63-0P
 615555-68-5P 879395-85-4P 879395-86-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (pyrrolidine derivs. of ketoamide-based cathepsin K inhibitors)
 RN 615554-78-4 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethylamino]acetyl]pentyl]-,
 (3S)-1-benzoyl-4,4-dimethyl-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 615554-94-4 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo{[(1R)-1-phenylethyl]amino}acetyl]pentyl]-, (3S)-1-(benzo[b]thien-2-ylcarbonyl)-4,4-dimethyl-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 615554-96-6 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo{[(1R)-1-phenylethyl]amino}acetyl]pentyl]-, (3S)-4,4-dimethyl-1-(2-naphthalenylcarbonyl)-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 615555-00-5 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo{[(1R)-1-phenylethyl]amino}acetyl]pentyl]-, (3S)-1-[(1,1'-biphenyl)-4-ylcarbonyl]-4,4-dimethyl-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 615555-34-5 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3,3-dimethyl-4-[[[(1S)-1-[oxo{[(1R)-1-phenylethyl]amino}acetyl]pentyl]amino]carbonyl]oxy]-, phenylmethyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 615555-35-6 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3,3-dimethyl-4-[[[(1S)-1-[oxo{[(1R)-1-phenylethyl]amino}acetyl]pentyl]amino]carbonyl]oxy]-, 2-phenylethyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 615555-47-0 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3,3-dimethyl-4-[[[(1S)-1-[oxo{[(1R)-1-phenylethyl]amino}acetyl]pentyl]amino]carbonyl]oxy]-, [1,1'-biphenyl]-4-yl ester, (4S)- (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 615555-02-7 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo{[(1R)-1-phenylethyl]amino}acetyl]pentyl]-, (3S)-1-(1H-indol-5-ylcarbonyl)-4,4-dimethyl-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 615555-09-4 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo{[(1R)-1-phenylethyl]amino}acetyl]pentyl]-, (3S)-4,4-dimethyl-1-(1-oxo-4-phenylbutyl)-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615555-30-1 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3,3-dimethyl-4-[[[(1S)-1-[oxo{[(1R)-1-phenylethyl]amino}acetyl]pentyl]amino]carbonyl]oxy]-, [1,1'-biphenyl]-4-ylmethyl ester, (4S)- (9CI) (CA INDEX NAME)


L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 615555-50-5 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3,3-dimethyl-4-[[[(1S)-1-[oxo{[(1R)-1-phenylethyl]amino}acetyl]pentyl]amino]carbonyl]oxy]-, 2-naphthalenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 615555-53-8 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo{[(1R)-1-phenylethyl]amino}acetyl]pentyl]-, (3S)-4,4-dimethyl-1-[(phenylamino)carbonyl]-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615555-55-0 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo{[(1R)-1-phenylethyl]amino}acetyl]pentyl]-, (3S)-4,4-dimethyl-1-[(2-phenylethyl)amino]carbonyl-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 615555-60-7 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethylamino]acetyl]pentyl]-, (3S)-4,4-dimethyl-1-[[4-(trifluoromethyl)phenyl]amino]carbonyl]-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 615555-63-0 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethylamino]acetyl]pentyl]-, (3S)-4,4-dimethyl-1-(4-morpholinylcarbonyl)-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 615555-68-5 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethylamino]acetyl]pentyl]-, (3S)-4,4-dimethyl-1-[(phenylmethyl)sulfonyl]-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethylamino]acetyl]pentyl]-, (3S)-tetrahydro-4,4-dimethyl-2-oxo-3-furanyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.


RN 879395-85-4 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethylamino]acetyl]pentyl]-, (3S)-4,4-dimethyl-1-(phenylmethyl)-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 879395-86-5 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3,3-dimethyl-4-[[[(1S)-1-[oxo[(1R)-1-phenylethylamino]acetyl]pentyl]amino]carbonyloxy]-, phenyl ester, (4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 615554-63-7
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pyrrolidine derivs. of ketoamide-based cathepsin K inhibitors)
 RN 615554-63-7 CAPLUS

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:331910 CAPLUS
 DOCUMENT NUMBER: 143:52911
 TITLE: A structural screening approach to ketoamide-based inhibitors of cathepsin K
 AUTHOR(S): Barrett, David G.; Catalano, John G.; Deaton, David N.; Long, Stacey T.; McFadyen, Robert B.; Miller, Aaron B.; Miller, Larry R.; Wells-Knecht, Kevin J.; Wright, Lois L.
 CORPORATE SOURCE: Department of Medicinal Chemistry, GlaxoSmithKline, Research Triangle Park, NC, 27709, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(9), 2209-2213
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 143:52911
 AB Several novel ketoamide-based inhibitors of cathepsin K have been identified. Starting from a modestly potent inhibitor, structural screening of P2 elements led to 100-fold enhancements in inhibitory activity. Modifications to one of these leads resulted in an orally bioavailable cathepsin K inhibitor.
 IT 615554-63-7P 615554-72-8P
 RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (structural screening approach to ketoamide-based inhibitors of cathepsin K)
 RN 615554-63-7 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethylamino]acetyl]pentyl]-, (3S)-tetrahydro-4,4-dimethyl-2-oxo-3-furanyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615554-72-8 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethylamino]acetyl]pentyl]-, (3S)-tetrahydro-4,4-dimethyl-2-oxo-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L4 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2003:836840 CAPLUS
DOCUMENT NUMBER: 139:338188
TITLE: Preparation of 1-(oxoaminoacetyl)pentylcarbamate derivatives as cathepsin K inhibitors for the treatment of bone loss
INVENTOR(S): Barrett, David Gene; Catalano, John G.; Deaton, David Norman; Miller, Aaron Bayne; Ray, John A.; Samano, Vicente
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 183 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

Instant App.

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003086385	A1	20031023	WO 2003-US9893	20030401
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VE, VU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003262140	A1	20031027	AU 2003-262140	20030401
EP 1494663	A1	20050112	EP 2003-746570	20030401
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005532290	T	20051027	JP 2003-583404	20030401
US 2005245596	A1	20051103	US 2004-510469	20041007
PRIORITY APPL. INFO.:			US 2002-371524P	P 20020410
			WO 2003-US9893	W 20030401

OTHER SOURCE(S): MARPAT 139:338188
AB Heterocycle-substituted ketoamide deriva. A-D-CONHCH₂[(CH₂)₄R]COCONH-Z [A is a group Q₄p-Q₃n-Q₂m-Q₁-, where Q₁ is heterocyclyl or heterocyclylene, Q₂ is OZC, CO, NHCO, CONHCO, SO₂NHCO, SO₂, or NHSO₂, Q₃ is C1-C6 alkyl, haloalkyl, C3-C7 cycloalkyl, aralkyl, aralkylene, aryl, arylene, heteroaryl, heteroarylene, heterocyclyl, or heterocyclylene, Q₄ is alkyl, haloalkyl, aryl, aryloxy, heteroaryl, halo, or cyano, m, n = 0 or 1 and p is 0-2; D is O or S; R is H or -NR₁-R₂-R₃, where R₁, R₂, R₃ are H or alkyl, R₂ is CO, CO₂, CONH, SO₂, or SO₂NH; Z is a group -Xm-Xl, where X is CR^{R'} (R', R'' are H or alkyl), m = 0-2 and Xl is aryl, heteroaryl, or heterocyclyl] were prepared for use as cathepsin K inhibitors. Comps.
of the invention are used in the manufacture of medicaments for the treatment of disorders, including osteoporosis, associated with an imbalance between bone


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
resorption and formation which can ultimately lead to fracture. Thus, (3S)-4,4-dimethyl-1-[[4-(trifluoromethyl)anilino]carbonyl]pyrrolidinyl (1S)-1-[oxo(1H-pyrazol-5-ylamino)acetyl]pentylcarbamate, prep. by a multistep procedure, showed IC₅₀ in the range 1-0.1 nM for inhibition of cathepsin K.

IT 615554-63-7P 615554-65-9P 615554-67-1P
615554-68-2P 615554-70-6P 615554-72-8P
615554-74-0P 615554-76-2P 615554-78-4P
615554-80-8P 615554-82-0P 615554-84-2P
615554-86-4P 615554-88-6P 615554-90-0P
615554-92-2P 615554-94-4P 615554-96-6P
615554-98-8P 615555-00-5P 615555-02-7P
615555-04-9P 615555-07-2P 615555-09-4P
615555-11-8P 615555-13-0P 615555-15-2P
615555-16-3P 615555-18-5P 615555-20-9P
615555-21-0P 615555-22-1P 615555-23-2P
615555-24-3P 615555-25-4P 615555-26-5P
615555-27-6P 615555-28-7P 615555-29-8P
615555-30-1P 615555-31-2P 615555-32-3P
615555-33-4P 615555-34-5P 615555-35-6P
615555-36-7P 615555-37-8P 615555-38-9P
615555-39-0P 615555-40-3P 615555-41-4P
615555-42-5P 615555-43-6P 615555-44-7P
615555-45-8P 615555-46-9P 615555-47-0P
615555-48-1P 615555-49-2P 615555-50-5P
615555-51-6P 615555-52-7P 615555-53-8P
615555-54-9P 615555-55-0P 615555-56-1P
615555-57-2P 615555-58-3P 615555-59-4P
615555-60-7P 615555-61-8P 615555-62-9P
615555-63-0P 615555-64-1P 615555-65-2P
615555-66-3P 615555-67-4P 615555-68-5P
615555-69-6P 615555-70-9P 615555-71-0P
615555-72-1P 615555-73-2P 615555-74-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of (oxoaminoacetyl)pentylcarbamate derivs. as cathepsin K inhibitors for treatment of bone loss)


RN 615554-63-7 CAPLUS
CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, (3S)-tetrahydro-4,4-dimethyl-2-oxo-3-furanyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 615554-65-9 CAPLUS
CN Carbamic acid, [(1S)-5-[[[(methylenamino)carbonyl]amino]-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, (3S)-tetrahydro-4,4-dimethyl-2-oxo-3-furanyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.




RN 615554-67-1 CAPLUS
CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, (4S)-4-ethyltetrahydro-4-methyl-2-oxo-3-furanyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 615554-68-2 CAPLUS
CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, 4,4-dimethyl-2-oxo-1-(phenylmethyl)-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615554-70-6 CAPLUS
CN 1-Pyrrolidinecarboxylic acid, 4,4-dimethyl-2-oxo-3-[[[(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]amino]carbonyloxy]-, phenylmethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 615554-72-8 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, (3S)-4,4-dimethyl-2-oxo-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 615554-74-0 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, 1,4,4-trimethyl-2-oxo-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615554-76-2 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, (3S)-4,4-dimethyl-1-(phenylmethyl)-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 615554-84-2 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, (3S)-1-(5-isoxazolylcarbonyl)-4,4-dimethyl-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 615554-86-4 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, (3S)-1-[(4-methyl-1,2,3-thiadiazol-5-yl)carbonyl]-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615554-88-6 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, (3S)-1-[(3-(1,1-dimethylethyl)-1-methyl-1H-pyrazol-5-yl)carbonyl]-4,4-dimethyl-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 615554-78-4 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, (3S)-1-benzoyl-4,4-dimethyl-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 615554-80-8 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, (3S)-1-acetyl-4,4-dimethyl-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615554-82-0 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, (3S)-1-(1,3-benzodioxol-5-ylcarbonyl)-4,4-dimethyl-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 615554-90-0 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, (3S)-1-(1,3-benzodioxol-5-ylcarbonyl)-4,4-dimethyl-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 615554-92-2 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, (3S)-1-(1,3-benzodioxol-5-ylcarbonyl)-4,4-dimethyl-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615554-94-4 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, (3S)-1-(benzo[b]thien-2-ylcarbonyl)-4,4-dimethyl-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 615554-96-6 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo{[(1R)-1-phenylethyl]amino}acetyl]pentyl]-, (3S)-4,4-dimethyl-1-(2-naphthalenylcarbonyl)-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 615554-98-8 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo{[(1R)-1-phenylethyl]amino}acetyl]pentyl]-, (3S)-4,4-dimethyl-1-[(1,1'-biphenyl)-4-ylcarbonyl]-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 615555-00-5 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo{[(1R)-1-phenylethyl]amino}acetyl]pentyl]-, (3S)-4,4-dimethyl-1-[(1,1'-biphenyl)-4-ylcarbonyl]-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 615555-09-4 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo{[(1R)-1-phenylethyl]amino}acetyl]pentyl]-, (3S)-4,4-dimethyl-1-[(1-oxo-4-phenylbutyl)-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 615555-11-8 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo{[(1R)-1-phenylethyl]amino}acetyl]pentyl]-, (3S)-4,4-dimethyl-1-[(1-methyl-1H-indol-2-yl)carbonyl]-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615555-13-0 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo{[(1R)-1-phenylethyl]amino}acetyl]pentyl]-, (3S)-4,4-dimethyl-1-[(2-(4-pyridinyl)-4-thiazolylcarbonyl)-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 615555-02-7 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo{[(1R)-1-phenylethyl]amino}acetyl]pentyl]-, (3S)-1-(1H-indol-5-ylcarbonyl)-4,4-dimethyl-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 615555-04-9 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo{[(1R)-1-phenylethyl]amino}acetyl]pentyl]-, (3S)-1-(1H-benzotriazol-5-ylcarbonyl)-4,4-dimethyl-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 615555-07-2 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo{[(1R)-1-phenylethyl]amino}acetyl]pentyl]-, (3S)-4,4-dimethyl-1-[(3-phenoxyphenyl)acetyl]-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 615555-15-2 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo{[(1R)-1-phenylethyl]amino}acetyl]pentyl]-, (3S)-4,4-dimethyl-1-[(5-methyl-3-phenyl-4-isoxazolyl)carbonyl]-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 615555-16-3 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo{[(1R)-1-phenylethyl]amino}acetyl]pentyl]-, (3S)-4,4-dimethyl-1-[(1-methyl-1H-indol-2-yl)carbonyl]-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615555-18-5 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo{[(1R)-1-phenylethyl]amino}acetyl]pentyl]-, (3S)-4,4-dimethyl-1-(3-quinolinylcarbonyl)-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 615555-20-9 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, (3S)-1-[(1,1'-biphenyl)-4-ylacetyl]-4,4-dimethyl-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 615555-21-0 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, (3S)-4,4-dimethyl-1-[(2-phenoxyphenyl)acetyl]-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615555-22-1 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, (3S)-1-(1H-indol-2-ylcarbonyl)-4,4-dimethyl-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 615555-26-5 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, (3S)-1-(1H-indol-3-ylcarbonyl)-4,4-dimethyl-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 615555-27-6 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, (3S)-4,4-dimethyl-1-[(2-(4-methyl-1,2,3-thiadiazol-5-yl)-4-thiazolyl)carbonyl]-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 615555-28-7 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, (3S)-4,4-dimethyl-1-[(2-pyrazinyl-4-thiazolyl)acetyl]-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 615555-23-2 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, (3S)-4,4-dimethyl-1-(3-pyridinylacetyl)-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 615555-24-3 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, (3S)-4,4-dimethyl-1-(1H-1,2,4-triazol-3-ylcarbonyl)-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615555-25-4 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, (3S)-1-(4-fluorophenylacetyl)-4,4-dimethyl-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.




RN 615555-29-8 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, (3S)-1-(4-fluorophenylacetyl)-4,4-dimethyl-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 615555-30-1 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3,3-dimethyl-4-[[[(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]amino]carbonyl]oxy]-, [1,1'-biphenyl]-4-ylmethyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615555-31-2 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3,3-dimethyl-4-[[[(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]amino]carbonyl]oxy]-, (tetrahydro-2-furanyl)methyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 615555-32-3 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3,3-dimethyl-4-[[[[(1S)-1-[oxo[[[(1R)-1-phenylethyl]amino]acetyl]pentyl]amino]carbonyl]oxy]-, 3-thienylmethyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 615555-33-4 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3,3-dimethyl-4-[[[[(1S)-1-[oxo[[[(1R)-1-phenylethyl]amino]acetyl]pentyl]amino]carbonyl]oxy]-, (3S)-tetrahydro-3-furanyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615555-34-5 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3,3-dimethyl-4-[[[[(1S)-1-[oxo[[[(1R)-1-phenylethyl]amino]acetyl]pentyl]amino]carbonyl]oxy]-, phenylmethyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 615555-38-9 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3,3-dimethyl-4-[[[[(1S)-1-[oxo[[[(1R)-1-phenylethyl]amino]acetyl]pentyl]amino]carbonyl]oxy]-, (tetrahydro-2H-pyran-2-yl)methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 615555-39-0 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3,3-dimethyl-4-[[[[(1S)-1-[oxo[[[(1R)-1-phenylethyl]amino]acetyl]pentyl]amino]carbonyl]oxy]-, (tetrahydro-3-furanyl)methyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615555-40-3 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3,3-dimethyl-4-[[[[(1S)-1-[oxo[[[(1R)-1-phenylethyl]amino]acetyl]pentyl]amino]carbonyl]oxy]-, (3',5-dimethyl[3,5'-bisoxazol]-4'-yl)methyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 615555-35-6 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3,3-dimethyl-4-[[[[(1S)-1-[oxo[[[(1R)-1-phenylethyl]amino]acetyl]pentyl]amino]carbonyl]oxy]-, 2-phenylethyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 615555-36-7 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3,3-dimethyl-4-[[[[(1S)-1-[oxo[[[(1R)-1-phenylethyl]amino]acetyl]pentyl]amino]carbonyl]oxy]-, (1-phenyl-1H-1,2,3-triazol-4-yl)methyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615555-37-8 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3,3-dimethyl-4-[[[[(1S)-1-[oxo[[[(1R)-1-phenylethyl]amino]acetyl]pentyl]amino]carbonyl]oxy]-, 2-(2-oxo-1-pyrrolidinyl)ethyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 615555-41-4 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3,3-dimethyl-4-[[[[(1S)-1-[oxo[[[(1R)-1-phenylethyl]amino]acetyl]pentyl]amino]carbonyl]oxy]-, 2-(4-methyl-5-thiazolyl)ethyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 615555-42-5 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3,3-dimethyl-4-[[[[(1S)-1-[oxo[[[(1R)-1-phenylethyl]amino]acetyl]pentyl]amino]carbonyl]oxy]-, (5-methyl-3-isoxazolyl)methyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615555-43-6 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3,3-dimethyl-4-[[[[(1S)-1-[oxo[[[(1R)-1-phenylethyl]amino]acetyl]pentyl]amino]carbonyl]oxy]-, [3-(2,6-dichlorophenyl)-5-methyl-4-isoxazolyl]methyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 615555-44-7 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3,3-dimethyl-4-[[[[(1S)-1-[[oxo[[[(1R)-1-phenylethyl]amino]acetyl]pentyl]amino]carbonyl]oxy]-, (2-methyl[1,1'-biphenyl]-3-yl)methyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 615555-45-8 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3,3-dimethyl-4-[[[[(1S)-1-[[oxo[[[(1R)-1-phenylethyl]amino]acetyl]pentyl]amino]carbonyl]oxy]-, (5-(2-thienyl)-1,2,4-oxadiazol-3-yl)methyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615555-46-9 CAPLUS


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 1-Pyrrolidinecarboxylic acid, 3,3-dimethyl-4-[[[[(1S)-1-[[oxo[[[(1R)-1-phenylethyl]amino]acetyl]pentyl]amino]carbonyl]oxy]-, 3-phenoxyphenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 615555-50-5 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3,3-dimethyl-4-[[[[(1S)-1-[[oxo[[[(1R)-1-phenylethyl]amino]acetyl]pentyl]amino]carbonyl]oxy]-, 2-naphthalenyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 615555-51-6 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3,3-dimethyl-4-[[[[(1S)-1-[[oxo[[[(1R)-1-phenylethyl]amino]acetyl]pentyl]amino]carbonyl]oxy]-, 4-(1,2,3-thiadiazol-4-yl)phenyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615555-52-7 CAPLUS


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 1-Pyrrolidinecarboxylic acid, 3,3-dimethyl-4-[[[[(1S)-1-[[oxo[[[(1R)-1-phenylethyl]amino]acetyl]pentyl]amino]carbonyl]oxy]-, (3R)-tetrahydro-3-furanyl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 615555-47-0 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3,3-dimethyl-4-[[[[(1S)-1-[[oxo[[[(1R)-1-phenylethyl]amino]acetyl]pentyl]amino]carbonyl]oxy]-, (1,1'-biphenyl)-4-yl ester, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 615555-48-1 CAPLUS
 CN 1-Pyrrolidinecarboxylic acid, 3,3-dimethyl-4-[[[[(1S)-1-[[oxo[[[(1R)-1-phenylethyl]amino]acetyl]pentyl]amino]carbonyl]oxy]-, 4-phenoxyphenyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615555-49-2 CAPLUS


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN 1-Pyrrolidinecarboxylic acid, 3,3-dimethyl-4-[[[[(1S)-1-[[oxo[[[(1R)-1-phenylethyl]amino]acetyl]pentyl]amino]carbonyl]oxy]-, phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 615555-53-8 CAPLUS
 CN Carbamic acid, [(1S)-1-[[oxo[[[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, (3S)-4,4-dimethyl-1-[(phenylmethyl)amino]carbonyl]-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 615555-54-9 CAPLUS
 CN Carbamic acid, [(1S)-1-[[oxo[[[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, (3S)-4,4-dimethyl-1-[(2-phenylethyl)amino]carbonyl]-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 615555-55-0 CAPLUS
 CN Carbamic acid, [(1S)-1-[[oxo[[[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, (3S)-4,4-dimethyl-1-[(2-phenylethyl)amino]carbonyl]-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.




RN 615555-56-1 CAPLUS
CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, (3S)-4,4-dimethyl-1-[(3-pyridinylcarbonyl)-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 615555-57-2 CAPLUS
CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, (3S)-1-[[4-(4-cyanophenyl)amino]carbonyl]-4,4-dimethyl-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615555-58-3 CAPLUS
CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, (3S)-1-[[4-(4-cyanophenyl)amino]carbonyl]-4,4-dimethyl-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, (3S)-4,4-dimethyl-1-[[4-(4-cyanophenyl)amino]carbonyl]-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 615555-62-9 CAPLUS
CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, (3S)-1-[[4-(4-cyanophenyl)amino]carbonyl]-4,4-dimethyl-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 615555-63-0 CAPLUS
CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, (3S)-4,4-dimethyl-1-[(4-morpholinylcarbonyl)-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.




RN 615555-59-4 CAPLUS
CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, (3S)-1-[[4-(4-cyanophenyl)amino]carbonyl]-4,4-dimethyl-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 615555-60-7 CAPLUS
CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, (3S)-4,4-dimethyl-1-[[4-(4-cyanophenyl)amino]carbonyl]-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 615555-61-8 CAPLUS

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 615555-64-1 CAPLUS
CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, (3S)-4,4-dimethyl-1-[(1-pyrrolidinylcarbonyl)-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 615555-65-2 CAPLUS
CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, (3S)-1-[(benzoylamino)carbonyl]-4,4-dimethyl-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 615555-66-3 CAPLUS
CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethyl]amino]acetyl]pentyl]-, (3S)-4,4-dimethyl-1-[[4-(4-methylphenyl)amino]carbonyl]-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 615555-67-4 CAPLUS


L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethylamino]acetyl]pentyl]-, (3S)-4,4-dimethyl-1-(phenylsulfonyl)-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 615555-68-5 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethylamino]acetyl]pentyl]-, (3S)-4,4-dimethyl-1-(phenylmethylsulfonyl)-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 615555-69-6 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethylamino]acetyl]pentyl]-, (3S)-1-(1,3-benzodioxol-5-ylsulfonyl)-4,4-dimethyl-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)




RN 615555-73-2 CAPLUS
 CN Carbamic acid, [1-[oxo[(1R)-1-phenylethylamino]acetyl]pentyl]-, (3S)-tetrahydro-4,4-dimethyl-3-furanyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 615555-74-3 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethylamino]acetyl]pentyl]-, (3R)-4,4-dimethyl-2-oxo-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L4 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)


RN 615555-70-9 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1R)-1-phenylethylamino]acetyl]pentyl]-, (3S)-1-[(2,3-dihydro-1,4-benzodioxin-6-yl)sulfonyl]-4,4-dimethyl-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 615555-71-0 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1H-pyrazol-3-ylamino]acetyl]pentyl]-, (3S)-1-(2-benzothiazolyl)-4,4-dimethyl-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 615555-72-1 CAPLUS
 CN Carbamic acid, [(1S)-1-[oxo[(1H-pyrazol-3-ylamino]acetyl]pentyl]-, (3S)-4,4-dimethyl-1-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]-3-pyrrolidinyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.